Ikarovec Seed
Norwich, GB · Founded 2018 · 10 employees on LinkedIn · 3 known investors
Find your way into Ikarovec Seed
154 people in our graph share verified history with the Ikarovec Seed team — schools, employers, funds. One of them is your warm intro.
Cathy Friedmanunlockedknows Thomas Ciulla, M.D, MBA · together at Harvard University (overlapped)
×10knows the team · via Harvard University
knows the team · via University of California, San Francisco
Ikarovec is a biotech company focused on developing treatments for retinal diseases affecting vision. The company combines clinical expertise with preclinical research capabilities.
Founders & leadership
Ikarovec Seed was founded in 2018 by Peter Widdowson, PhD.
PW
Peter Widdowson, PhDScientific Founder
TC
Thomas Ciulla, M.D, MBAinPresident and Chief Executive OfficerDr. Thomas Ciulla is a retinal specialist trained at Harvard, UCSF, and Tufts with an MBA focused on healthcare business, and brings 25+ years of executive and clinical leadership spanning drug development, gene therapy, and rare disease treatment. He previously held chief medical and development roles at Spark Therapeutics, Iveric Bio, Clearside Biomedical, and Viridian Therapeutics, contributing to multiple FDA-approved ophthalmic therapies including the first approved gene therapy for inherited retinal disease and the first suprachoroidal therapy.
Investors · 3
Frequently asked questions
- What does Ikarovec Seed do?
- Ikarovec is a biotech company focused on developing treatments for retinal diseases affecting vision. The company combines clinical expertise with preclinical research capabilities.
- Who founded Ikarovec Seed?
- Ikarovec Seed was founded by Peter Widdowson, PhD in 2018.
- Who are Ikarovec Seed's investors?
- Ikarovec Seed's investors include LifeArc Ventures, Future Planet Capital, UK Innovation & Science Seed Fund.
- Where is Ikarovec Seed headquartered?
- Ikarovec Seed is headquartered in Norwich, GB.